Eagle Bay Advisors’s Cytokinetics CYTK Stock Holding History

Eagle Bay Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-57	Closed	-$2.68K	–	318
2024 Q4	$2.68K	Hold	57	–	–	﹤0.01%	811
2024 Q3	$3.01K	Hold	57	–	–	﹤0.01%	1134
2024 Q2	$3.09K	Hold	57	–	–	﹤0.01%	820
2024 Q1	$4K	Hold	57	–	–	﹤0.01%	778
2023 Q4	$4.76K	Hold	57	–	–	﹤0.01%	641
2023 Q3	$1.68K	Hold	57	–	–	﹤0.01%	779
2023 Q2	$1.86K	Hold	57	–	–	﹤0.01%	773
2023 Q1	$2.01K	Hold	57	–	–	﹤0.01%	758
2022 Q4	$2.61K	Hold	57	–	–	﹤0.01%	736
2022 Q3	$3K	Hold	57	–	–	﹤0.01%	724
2022 Q2	$2.24K	Buy	+57	New	+$2.29K	﹤0.01%	810
2022 Q1	–	Sell	-57	Closed	-$3K	–	449
2021 Q4	$3K	Buy	+57	New	+$2.2K	﹤0.01%	858

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Eagle Bay Advisors's CYTK Position: Q1 2025 in Review

Eagle Bay Advisors sold out of Cytokinetics (CYTK) in Q1 2025, closing a stake of 57 shares — an estimated $2.68K sold.

Eagle Bay Advisors first reported a position in CYTK in Q4 2021 and held it in 12 quarters. The position peaked at $4.76K in Q4 2023. 355 funds tracked by Wall St. Rank hold CYTK as of Q1 2025.

Eagle Bay Advisors reported no remaining Cytokinetics position as of Q1 2025 after selling out during the quarter.
Eagle Bay Advisors sold 57 Cytokinetics shares in Q1 2025, an estimated $2.68K.
Eagle Bay Advisors first reported a position in Cytokinetics in Q4 2021 and held it in 12 quarters.
Eagle Bay Advisors's Cytokinetics position peaked at $4.76K in Q4 2023.
355 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2025.

Based on Eagle Bay Advisors's 13F filing for Q1 2025, filed 5 May 2025.